Hot Investor Mandate: Venture Firm Makes Life Science Investments at Series A and Beyond

25 Apr

A venture capital firm is investing out of their second fund of over $200 million.  The firm invests via relationships with universities, and also in external startups that are not from these partnerships.  The firm typically makes initial investments of $1M-$5M and allocates up to $10M over the life of the investment. The firm usually invests in Series A rounds and beyond, but only participates as a part of a syndicate where a lead investor has already been identified. Further, the firm only invests alongside other institutional capital.

Though the firm does not have a strict mandate in terms of subsector or indication, therapeutics for oncology, cardiovascular, anti-inflammatories, and ophthalmology drugs have historically done well and are favored by the investment team. In addition to therapeutics, the firm will consider diagnostics and medical devices, but has not been active in these sectors.

The firm prefers an experienced management team with a successful track record, and primarily invests in U.S. and Canadian companies. The firm does not typically seek a board seat along with an investment, but may take an observer seat in the event the company’s management team is inexperienced.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: